FINA and ANTi E's

**DieselLeo** · 10-29-2002, 01:38 PM

I am about to start my cycle which includes Test Enanthate , D-bol, EQ, Winnie and Fina. As of now I am planning on using Arimidex as my anti estrogen. Will Arimidex work well against Fina gyno ? Or should I try to get my hands on Bromine or Teslac or Novladex ? Thanks for the help

**McBain** · 10-29-2002, 01:41 PM

No you should get some bromo to have on hand. I'd have nolv on hand too.

**nj_** · 10-29-2002, 01:56 PM

If you can get dostinex over bromo I'd take it, less side effects, less dosages. Arimidex will do nothing for prolactin induced gyno so better have the bromo (or dostinex) on hand.

**dizzle** · 10-29-2002, 04:49 PM

I did a search on dostinex, looks like a viagra alternative.

**nj_** · 10-29-2002, 06:12 PM

Here's a study on the advantages of Dostinex over Bromocriptine, Where did you see this data of it being a viagra alternative, dizzle?

Until Dostinex became available in the U.S., the only other dopamine agonist approved for the treatment of prolactinomas and/or hyperprolactinemia was bromocriptine. However, Dostinex has proved to have a number of advantages over bromocriptine:

Lower incidence of side effects
Twice weekly dosing versus 2-3 times daily for bromocriptine
Generally more effective, especially in those in which bromocriptine was ineffective

Disadvantages of Dostinex over Bromocriptine

Dostinex is twice as expensive as bromocriptine
Dostinex is not available in all countries
Dostinex is not approved for use during pregnancy, and its effects on pregnancy are unknown at this time

Side Effects

The side effects associated with Dostinex usually disappear or are reduced after a few doses. However, if you miss a dose, you may experience some of the original side effects for a short time. The most common side effects of Dostinex are:

Nausea
Dizziness
Sleepiness
Headache
Stuffy nose
Clinical Trial Results

Webster et al., 1994. Comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 31: 904-909.

459 women with either microprolactinoma or idiopathic hyperprolactinemia were treated with Dostinex or bromocriptine in a double blind study for eight weeks.

Results:

Attainment of normal prolactin levels: 83% on Dostinex 59% on Bromocriptine

Attainment of ovulatory cycles or pregnancy: 72% on Dostinex 52% on Bromocriptine

Return of monthly periods: 93% on Dostinex 84% on Bromocriptine

Dostinex had significantly less side effects with shorter duration and less severity that bromocriptine. Only 3% of women on Dostinex quit treatment because of side effects versus 12% that stopped treatment due to intolerance on bromocriptine.
Biller BMK, et al. 1996. Treatment of prolactin secreting macroadenomas with once weekly agonist cabergoline. J Clin Endocrinol Metab 81: 2338-2343.

15 patients (8 women, 7 men) were treated with Dostinex, once weekly, for 48 weeks.

Results:

A 93.6% reduction in prolactin levels, with normal levels obtained in 73% of patients
5 patients who had previously been unable to achieve normal prolactin levels on other dopamine agonists, achieved normal prolactin levels on Dostinex
gonadal function was restored in all hypogonadal men
75% of premenopausal women with amenorrhea experienced return of gonadal function
11 of 15 patients experienced tumor shrinkage
minimal side effects – no patients discontinued Dostinex because of intolerance
Colao, A. et al. 1997. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11): 3574-3579.

23 patients with macroprolactinomas Results:

normalization of prolactin levels in 18 patients within 3-6 months at 0.5 mg/week
tumor volume reduction greater than 80% occurred in 61% of patients at the 12-24 month follow-up
the complete disappearance of the tumor occurred after 6 months in one patient and after 1 year of treatment in 5 patients
visual field defects were improved in 90% of patients who experienced them
Conclusions

In general, the data suggests that Dostinex is a better tolerated and a more effective dopamine agonist that bromocriptine in the treatment of prolactinomas. Dostinex effectively lowers prolactin levels and shrinks tumor size in a high percentage of cases, making it a good first option in the treatment of both micro- and macroprolactinomas.